Daily Technical Summary Reports on Medical Research Stocks -- Exact Sciences, HTG Molecular Diagnostics, Roka Bioscience, and OpGen

Saturday, November 4, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 03, 2017 /PRNewswire/ --

If you want a Stock Review on EXAS, HTGM, ROKA, or OPGN then come over to

http://dailystocktracker.com/register/ and sign up for your free customized report. Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. These firms, as a whole,
tend to offer higher dividend yields than the wider Healthcare sector. Pre-market today, DailyStockTracker.com draws investors' attention to the following equities: Exact Sciences Corp. (NASDAQ: EXAS), HTG Molecular Diagnostics Inc. (NASDAQ: HTGM), Roka Bioscience Inc. (NASDAQ: ROKA), and OpGen Inc. (NASDAQ: OPGN). Register now and get full and free access to these DailyStockTracker.com research reports at: http://dailystocktracker.com/register/

Exact Sciences

On Thursday, shares in Madison, Wisconsin headquartered Exact Sciences Corp. recorded a trading volume of 1.66 million shares, which was above their three months average volume of 1.55 million shares. The stock ended at $54.98, climbing 3.72% from the last trading session. The Company's shares have surged 14.57% in the last one month, 42.10% over the previous three months, and 311.53% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 20.24% and 65.44%, respectively. Furthermore, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have a Relative Strength Index (RSI) of 70.20. 

On November 01st, 2017, research firm BTIG Research downgraded the Company's stock rating from 'Buy' to 'Neutral'.

On November 02nd, 2017, Exact Sciences announced that Jeff Elliott, CFO, will present at the Canaccord Medical Technologies & Diagnostics Forum on November 09th, 2017 at 9:30 a.m. EST in New York. Mr. Elliott will also make a Company presentation at the Jefferies 2017 London Healthcare Conference on November 16th, 2017, at 4:20 a.m. EST in London. Access our complete research report on EXAS for free at: http://dailystocktracker.com/registration/?symbol=EXAS

HTG Molecular Diagnostics

Tucson, Arizona-based HTG Molecular Diagnostics Inc.'s stock finished yesterday's session 4.87% higher at $2.37 with a total trading volume of 328,366 shares. The Company's shares have gained 31.67% in the last one month, 5.80% over the previous three months, and 5.80% on an YTD basis. The stock is trading above its 50-day moving average by 18.00%. Furthermore, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have an RSI of 54.97. 

On October 20th, 2017, HTG Molecular Diagnostics announced that it will report its financial results for the three and nine months ended September 30th, 2017, after the market close on November 07th, 2017. Management will also host a conference call at 4:30 p.m. ET that same day to discuss the financial results and provide a corporate update. The complimentary research report on HTGM can be downloaded at: http://dailystocktracker.com/registration/?symbol=HTGM

Roka Bioscience

At the close of trading on Thursday, shares in Warren, New Jersey headquartered Roka Bioscience Inc. jumped 6.03%, ending the day at $1.23. The stock recorded a trading volume of 546,669 shares. The Company's shares have surged 61.97% in the last one month. The stock is trading 3.68% above its 50-day moving average. Moreover, shares of Roka Bioscience, which focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the US, have an RSI of 48.54. Register for free on DailyStockTracker.com and get access to the latest report on ROKA at: http://dailystocktracker.com/registration/?symbol=ROKA

OpGen

Gaithersburg, Maryland headquartered OpGen Inc.'s shares ended the day 1.16% higher at $0.29 with a total trading volume of 1.59 million shares. The stock is trading 4.23% below its 50-day moving average. Shares of the Company, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have an RSI of 41.74. 

On October 26th, 2017, OpGen announced that it will report its Q3 2017 financial results after close of market on November 07th, 2017. The management team will host a live conference call and webcast at 4:30 p.m. ET that same day to discuss the Company's financial results and business progress. The live, listen-only webcast of the conference call may be accessed under the investors section of the Company's website. Download your free research report on OPGN at: http://dailystocktracker.com/registration/?symbol=OPGN

--

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

Contact:

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

View original content:http://www.prnewswire.com/news-releases/daily-technical-summary-reports-on-medical-research-stocks----exact-sciences-htg-molecular-diagnostics-roka-bioscience-and-opgen-300549222.html

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store